D-0326-2022 Class III Terminated

Recalled by Lupin Pharmaceuticals Inc. — Baltimore, MD

FDA drug recall D-0326-2022 was initiated by Lupin Pharmaceuticals Inc. on Dec 22, 2021 and is designated Class III. Reason for recall: Failed Stability Specifications: Out-of-specification results observed in a water loss test that might affect the assay content and alter drug concentration. The recall status is terminated (terminated Sep 12, 2022). Affected quantity: 50,832 bottles.

Recall details

Product Type
Drugs
Report Date
Jan 12, 2022
Initiation Date
Dec 22, 2021
Termination Date
Sep 12, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
50,832 bottles

Product description

Gatifloxacin Ophthalmic Solution, 0.5%, 2.5 mL bottle, Rx only, Manufactured by: Lupin Limited, Pithampur (M.P.) 454 775, INDIA, NDC 68180-435-01.

Reason for recall

Failed Stability Specifications: Out-of-specification results observed in a water loss test that might affect the assay content and alter drug concentration.

Distribution pattern

Nationwide in the USA and Puerto Rico

Code information

Lot #: H003037, exp. date May 2022; H100132, exp. date June 2022; H100847, exp. date October 2022

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0326-2022
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0326-2022. Report a data issue: hello@regdatalab.com.